查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403379

2030 年临床前 CRO（委外研发机构）市场预测：按模型类型、服务、动物模型、最终用户和地区进行的全球分析

Preclinical Contract Research Organization Market Forecasts to 2030 - Global Analysis By Model Type, Service, Animal Model, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球临床前CRO（委外研发机构）市场规模将达到49.9亿美元，预测期内复合年增长率为9.5%，预计到2030年将达到94.2亿美元。

临床前委外研发机构（CRO）是製药和生物技术行业的专业服务供应商，在实验药物和治疗方法进入临床试验之前对其进行研究和测试。临床前 CRO 提供广泛的服务来评估新化合物的安全性、有效性和风险。此外，临床前 CRO 的知识和资源可以透过提供关键资讯和监管支援以及遵守监管和行业规范来帮助优化药物开发。

根据IFPMA 2021年报告，国际生物製药产业的年度研发支出比航太和国防工业高7.3倍，比化学工业高6.5倍，比软体和电脑服务业高出1.5倍。

全球化进程

CRO 是一家国际企业，为製药和生技公司提供多个司法管辖区的广泛资源、知识和监管管道。透过利用监管优势、多样化的患者群体和新兴市场，公司可以透过全球化优化其药物开发策略。此外，透过促进合作和创新以及加快新药的上市时间和效率，我们可以改善医疗保健成果并改善公众获得尖端治疗的机会。

高成本

遵守严格法规和维持品质标准的需要增加了费用。为了正确地进行临床前研究，CRO 必须投入大量资金购买最先进的设施、机械和高素质的员工。激烈的竞争对 CRO 来说是常见的，提高了市场竞争的价格和业务开拓。此外，由于这些高昂的成本，小型或新的 CRO 可能很难进入市场，从而阻碍市场成长。

技术进步

製药和生物技术公司可以利用先进技术做出更好的药物开发决策。 CRO 利用这些特定知识来降低开发风险，加快识别有前途的候选药物，并提高新治疗方法的整体品质和安全性。此外，CRO 的专业知识和经验使他们成为在严格的政府监管范围内推动药物开发和创新、扩大市场规模的有利盟友。

严格的法规环境

在这一领域运营的 CRO 面临复杂法律规范的挑战，这可能导致合规成本增加和计划进度延迟。严格的法规环境也会影响製药和生技公司选择 CRO 合作伙伴时的决策流程。此外，监管负担导致核准流程延长和检查增加，影响 CRO 进行临床前研究的整体有效性和进度。这种不利的环境抑制了创新，降低了临床前研究服务的可用性，并抑制了市场扩张。

COVID-19 的影响

COVID-19的疫情对临床前CRO（委外研发机构）市场产生了显着的负面影响。延迟或取消的临床前试验数量减少了对 CRO 服务的需求。疫情造成的财务不确定性减少了研发投资，影响了为外包临床前测试预留的资金。此外，景气衰退和疫情造成的不确定性导致一些客户推迟或取消临床前研究，影响CRO收益和成长前景，进一步阻碍该市场。

预计预测期内毒理学测试领域规模最大

预计毒理学检测领域将占据最大份额。专门从事毒理学的 CRO 透过彻底评估潜在药物以满足严格的监管标准，为生物技术和製药公司提供关键服务。这些测试透过评估化学物质如何影响各种生物系统来帮助发现不良反应和给药。因此，我们透过最大限度地降低开发风险、加快监管核准和确保药物安全来保护公共卫生和药物开发倡议的成功，从而推动该领域的成长。

患者来源的异质骨移植（PDX）领域预计在预测期内复合年增长率最高

患者来源的异质骨移植（PDX）领域预计在预测期内复合年增长率最高。这是由于 PDX 模型，将患者的肿瘤组织移植到免疫力缺乏小鼠体内，以重建患者的肿瘤环境。如果候选药物在更临床相关的环境中进行评估，这些模型更有可能在人体试验中取得成功。此外，PDX CRO 还提供个体化医疗见解，为特定患者提供治疗。由于精准医疗的重要性日益增加，PDX 市场对于进一步开发高效、有针对性的癌症治疗至关重要，推动了这一领域的扩张。

比最大的地区

由于促进製药公司和 CRO 之间顺利资料交换和协作的整合平台的成长，亚太地区在预测期内获得了最大的市场占有率。 Covance Inc.、Medpace Holdings, Inc.、MPI Research 和 Eurofins Scientific 等主要企业为国际合作提供了有吸引力的环境，并为全球製药和生物技术行业的发展做出了贡献。此外，政府支持的增加、监管的协调以及高通量筛检、机器学习和资料处理人工智慧等技术进步正在推动该地区的扩张。

复合年增长率最高的地区：

鑑于北美在药物开发临床前阶段对支持製药和生物技术公司的关键作用，预计在预测期内复合年增长率最高。美国、加拿大和墨西哥地区的特点是强大的基础设施、最尖端科技和高技能的劳动力。这些领域包括药理学、毒理学、生物分析以及对监管核准至关重要的各种其他临床前研究。此外，该地区的 CRO 受益于有利的法规环境以及与学术机构的合作，促进创新和专业知识，并支持该地区的成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球临床前CRO（委外研发机构）市场：依模型类型

  • 患者异质骨移植（PDX）
  • 患者来源的类器官 (PDO)

第六章全球临床前 CRO（委外研发机构）市场：依服务分类

  • 安全药理学
  • 生物分析以及药物代谢和药物动力学 (DMPK) 研究
    • 体外药物动力学（PK）
    • 体内药物动力学（PK）
  • 毒性试验
  • 化学
    • 计算化学
    • 药物化学
  • 复合管理
    • 製程研发
    • 自订合成
    • 其他综合管理
  • 其他服务

第七章全球临床前CRO（委外研发机构）市场：依动物模型

  • 大型动物模型
  • 小动物模型

第八章全球临床前 CRO（委外研发机构）市场：依最终使用者分类

  • 政府和学术机构
  • 医疗设备公司
  • 生物製药公司
  • 其他最终用户

第九章全球临床前CRO（委外研发机构）市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Crown Bioscience
  • Eurofins Scientific
  • Laboratory Corporation of America, Inc.
  • PRA Health Sciences, Inc.
  • Intertek Group Plc（IGP）
  • Wuxi AppTec
  • SGS SA（SGS）
  • Medpace, Inc.
  • Pharmaceutical Product Development（PPD）, LLC
  • Charles River Laboratories International, Inc.
  • PPD（Thermo Fisher Scientific, Inc.）
  • WuXi AppTec, Inc.（WAI）
Product Code: SMRC24604

According to Stratistics MRC, the Global Preclinical Contract Research Organization (CRO) Market is accounted for $4.99 billion in 2023 and is expected to reach $9.42 billion by 2030 growing at a CAGR of 9.5% during the forecast period. A Preclinical Contract Research Organization (CRO) is a specialized service provider in the pharmaceutical and biotechnology industry that conducts research and testing on experimental drugs and therapies before they enter clinical trials. To evaluate the safety, efficacy, and possible dangers associated with novel compounds, preclinical CROs provide a broad range of services. Furthermore, their knowledge and resources aid pharmaceutical businesses in optimizing drug development by offering vital information and regulatory support and by providing adherence to regulatory and industry norms.

According to the IFPMA's 2021 report, the annual R&D spending by the international biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Increase in globalization

CROs are international businesses that provide pharmaceutical and biotech firms with access to a wide range of resources, knowledge, and regulatory routes in several jurisdictions. By taking advantage of regulatory benefits, diversified patient populations, and developing markets, corporations can optimize their drug development strategy through globalization. Additionally, it improves healthcare outcomes and public access to cutting-edge therapeutics by encouraging cooperation and innovation and accelerating the time and efficiency of bringing new drugs to market.

Restraint:

High cost

The need to adhere to stringent regulatory regulations and uphold quality standards increases expenditures. To properly undertake preclinical research, CROs must invest a significant amount of money in cutting-edge facilities, machinery, and highly qualified staff. Intense competition is a common occurrence for CROs, which raises the price of marketing and business development initiatives. In addition, smaller or newly established CROs may find it difficult to enter the market due to these exorbitant costs, which thereby hinder market growth.

Opportunity:

Technological advancements

Pharmaceutical and biotech businesses may make well-informed judgments on drug development with the help of their advanced technologies, which enables them to provide reliable and efficient preclinical testing and data analysis. CROs use this specific knowledge to lower development risks, speed up the identification of promising drug candidates, and improve the general quality and safety of novel treatments. Furthermore, because of their specialization and experience, CROs are advantageous collaborators for promoting drug development and innovation in a tough, government-regulated setting thereby driving this market size.

Threat:

Stringent regulatory environment

CROs operating in this space encounter challenges in navigating the intricate regulatory frameworks, leading to increased compliance costs and potential delays in project timelines. The stringent regulatory environment also influences the decision-making process of pharmaceutical and biotechnology companies when selecting CRO partners. Furthermore, the regulatory load results in longer approval processes and more inspection, affects the general effectiveness and pace of preclinical research carried out by CROs. This unfavourable environment inhibits innovation, lowers the availability of preclinical research services, and thereby impedes this market expansion.

COVID-19 Impact

The COVID-19 pandemic has had a notable negative impact on the preclinical contract research organization (CRO) market. The number of preclinical studies that were postponed or cancelled resulted in a decline in the need for CRO services. The pandemic's financial insecurity has resulted in decreased investment in research and development, which has an effect on the money set aside for preclinical study outsourcing. Furthermore, the pandemic-induced economic downturn and uncertainty prompted some clients to postpone or cancel preclinical projects, impacting the revenue and growth prospects of CRO and further impeding this market.

The toxicology testing segment is expected to be the largest during the forecast period

The toxicology testing segment is estimated to hold the largest share. Toxicology-focused CROs offer vital services to biotech and pharmaceutical firms by thoroughly assessing potential drugs in order to satisfy strict regulatory standards. These tests help discover harmful reactions and dosage levels by assessing how chemicals affect different biological systems. Therefore, it protects public health and the success of drug development initiatives by minimizing development risks, expediting regulatory approvals, and guaranteeing the safety of pharmaceutical goods, which thereby boosts this segment's growth.

The patient derived xenograft (PDX) segment is expected to have the highest CAGR during the forecast period

The patient derived xenograft (PDX) segment is anticipated to have highest CAGR during the forecast period due to the tumor tissues from patients being transplanted into immunodeficient mice in PDX models to replicate the tumor environment of the patient. These models show a greater chance of success in human trials when drug candidates are evaluated in a more clinically appropriate setting. Furthermore, customized medicine insights are provided by PDX CROs, enabling treatmentsfor specific patients. The PDX market is essential for further developing efficient and targeted cancer treatments because of the growing significance of precision medicine, thereby driving this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the growth of integrated platforms that facilitate smooth data exchange and cooperation between pharmaceutical corporations and CROs. Key players such as Covance Inc., Medpace Holdings, Inc., MPI Research, and Eurofins Scientific offer a compelling environment for international collaborations and are establishing themselves in advancing the global pharmaceutical and biotechnology industries. Additionally, growing government support, regulatory harmonization, and technological advancements such as high-throughput screening, machine learning, and artificial intelligence for data processing drive this region's expansion.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to its pivotal role in supporting pharmaceutical and biotechnology companies in the preclinical phase of drug development. The United States, Canada, and Mexico regions are characterized by a robust infrastructure, cutting-edge technology, and a highly skilled workforce. They include pharmacology, toxicology, bioanalysis, and various other preclinical studies essential for regulatory approval. Furthermore, the region's CROs benefit from a favorable regulatory environment and collaboration with academic institutions, fostering innovation and expertise that are propelling this region's growth.

Key players in the market:

Some of the key players in the Preclinical Contract Research Organization (CRO) Market include Crown Bioscience, Eurofins Scientific, Laboratory Corporation of America, Inc., PRA Health Sciences, Inc., Intertek Group Plc (IGP), Wuxi AppTec, SGS SA (SGS), Medpace, Inc., Pharmaceutical Product Development (PPD), LLC, Charles River Laboratories International, Inc., PPD (Thermo Fisher Scientific, Inc.) and WuXi AppTec, Inc. (WAI).

Key Developments:

In November 2023, Intertek, announced the launch of iCare in Turkiye, one of its most successful markets. iCare is an innovative one-stop digital portal providing textile manufacturers with a pioneering solution that enables seamless management and monitoring of their testing processes from start to finish.

In October 2023, SGS is signed an agreement to divest its US powertrain testing operations as part of its strategic portfolio evolution to Columbia River Partners, a private equity firm focused on the industrials, business services and IT services sectors, headquartered in California.

In September 2023, Intertek, proudly announced the integration of advanced PhotonAssay technology into its Minerals laboratory facility in Tarkwa, Ghana. With a legacy of excellence and a commitment to innovation, Intertek Minerals aims to revolutionise gold industry support in West Africa through the implementation of this groundbreaking technology.

Model Types Covered:

  • Patient Derived Xenograft (PDX)
  • Patient Derived Organoid (PDOs)

Services Covered:

  • Safety Pharmacology
  • Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
  • Toxicology Testing
  • Chemistry
  • Compound Management
  • Other Services

Animal Models Covered:

  • Large Animal Model
  • Small Animal Model

End Users Covered:

  • Government and Academic Institutes
  • Medical Device Companies
  • Biopharmaceutical Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preclinical Contract Research Organization (CRO) Market, By Model Type

  • 5.1 Introduction
  • 5.2 Patient Derived Xenograft (PDX)
  • 5.3 Patient Derived Organoid (PDOs)

6 Global Preclinical Contract Research Organization (CRO) Market, By Service

  • 6.1 Introduction
  • 6.2 Safety Pharmacology
  • 6.3 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
    • 6.3.1 In vitro Pharmacokinetics (PK)
    • 6.3.2 In-vivo Pharmacokinetics (PK)
  • 6.4 Toxicology Testing
  • 6.5 Chemistry
    • 6.5.1 Computation Chemistry
    • 6.5.2 Medicinal Chemistry
  • 6.6 Compound Management
    • 6.6.1 Process R&D
    • 6.6.2 Custom Synthesis
    • 6.6.3 Other Compound Managements
  • 6.7 Other Services

7 Global Preclinical Contract Research Organization (CRO) Market, By Animal Model

  • 7.1 Introduction
  • 7.2 Large Animal Model
  • 7.3 Small Animal Model

8 Global Preclinical Contract Research Organization (CRO) Market, By End User

  • 8.1 Introduction
  • 8.2 Government and Academic Institutes
  • 8.3 Medical Device Companies
  • 8.4 Biopharmaceutical Companies
  • 8.5 Other End Users

9 Global Preclinical Contract Research Organization (CRO) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Crown Bioscience
  • 11.2 Eurofins Scientific
  • 11.3 Laboratory Corporation of America, Inc.
  • 11.4 PRA Health Sciences, Inc.
  • 11.5 Intertek Group Plc (IGP)
  • 11.6 Wuxi AppTec
  • 11.7 SGS SA (SGS)
  • 11.8 Medpace, Inc.
  • 11.9 Pharmaceutical Product Development (PPD), LLC
  • 11.10 Charles River Laboratories International, Inc.
  • 11.11 PPD (Thermo Fisher Scientific, Inc.)
  • 11.12 WuXi AppTec, Inc. (WAI)

List of Tables

  • Table 1 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 3 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 4 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 5 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 6 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 7 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 8 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 9 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 10 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 11 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 12 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 13 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 14 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 15 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 16 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 17 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 18 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 19 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 20 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 21 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 22 Global Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 24 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 25 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 26 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 29 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 30 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 31 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 32 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 33 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 34 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 35 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 36 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 37 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 38 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 39 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 40 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 41 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 42 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 43 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 44 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 45 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 46 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 47 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 48 North America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 50 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 51 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 52 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 55 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 56 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 57 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 58 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 59 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 60 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 61 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 62 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 63 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 64 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 65 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 66 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 67 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 68 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 69 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 70 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 71 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 72 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 73 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 74 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 76 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 77 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 78 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 82 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 83 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 84 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 85 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 86 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 87 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 88 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 89 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 90 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 91 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 92 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 93 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 94 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 95 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 96 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 97 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 98 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 99 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 100 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 102 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 103 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 104 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 107 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 108 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 109 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 110 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 111 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 112 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 113 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 114 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 115 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 116 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 117 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 118 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 119 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 120 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 121 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 122 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 123 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 124 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 125 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 126 South America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 128 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 129 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 130 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 134 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 135 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 136 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 137 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 138 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 139 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 140 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 141 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 142 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 143 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 144 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 145 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 146 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 147 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 148 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 149 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 150 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 151 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 152 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 154 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 155 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 156 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)